Evogene Announces Leadership Change and Strategic Shift at Biomica

Evogene ( (EVGN) ) has issued an announcement.

Evogene Ltd. announced a significant management change in its subsidiary, Biomica Ltd., due to the unexpected medical condition of Dr. Elran Haber, Biomica’s CEO. Effective June 8, 2025, Mr. Ofer Haviv, Evogene’s President and CEO, will assume the role of Biomica’s CEO. Additionally, Biomica will reduce its internal R&D activities and workforce, while continuing trials of its clinical phase I product BMC128, seeking third-party collaboration for further development. This strategic shift aligns with Evogene’s plan to create a more capital-efficient business model, focusing on generating cash flow and unlocking the potential of its ChemPass-AI technology.

The most recent analyst rating on (EVGN) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.

Spark’s Take on EVGN Stock

According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.

The overall stock score reflects significant financial challenges, including negative cash flows and profitability issues, which are the most critical factors. Technical analysis suggests limited positive momentum, and the valuation remains unattractive due to the negative P/E ratio. Despite some strategic improvements highlighted in the earnings call, the company’s financial instability remains a major concern.

To see Spark’s full report on EVGN stock, click here.

More about Evogene

Evogene Ltd. is a biotechnology company focused on developing products based on computational biology. Its primary focus is on the human microbiome, with a significant market interest in drug development and agricultural biotechnology.

Average Trading Volume: 374,034

Technical Sentiment Signal: Strong Sell

Current Market Cap: $7.41M

Find detailed analytics on EVGN stock on TipRanks’ Stock Analysis page.